SNY Sanofi American Depositary Shares (Each representing one-half of one ordinary share)

Sentiment & Price 5 ideas • 3 voices • 3 sources ▼
Sentiment Gauge
0
Bull
0
Bear
0
Watch
Bull 50% Bear 50%
Price & Sentiment
Loading chart...
Recent News Top Views ▼
No recent news for SNY
No theses available
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
News✓
Loading...
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
18:13
Mar 28
A May MD Biotech investor
The tweet highlights alarming safety concerns regarding rapid cancer development linked to OX40-induced treatments.
SNY
17:27
Mar 28
A May MD Biotech investor
The tweet suggests potential clinical trial failures for Sanofi and Nektar Therapeutics, signaling a negative outlook for both companies.
SNY
16:30
Mar 28
A May MD Biotech investor
The author highlights safety concerns regarding Sanofi's amlitelimab and questions Nektar Therapeutics' valuation in light of these developments.
SNY
17:45
Mar 06
@ReutersBiz
Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million https://t.co/wXcW78Sj9j https://t.co/wXcW78Sj9j
SNY
06:05
Feb 20
@firstsquawk
A major sell-side bank is lowering its price target, indicating a revised, more bearish outlook on the stock's forward performance.
SNY
MED

About SNY Analyst Coverage

Buzzberg tracks SNY (Sanofi American Depositary Shares (Each representing one-half of one ordinary share)) across 3 sources. 0 bullish vs 4 bearish calls from 3 analysts. Sentiment: mixed to bearish. 5 total trade ideas tracked.